A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies.

Abstract:

:Aging entails the accumulation of neoantigens comprised of aggregated, oxidized, mutated and misfolded biomolecules, including advanced-glycation end projects (AGEs). There is evidence that the immune system can recognize and clear cells fouled by these molecular debris, which contribute to the emergence of cancer and other major age-associated diseases such as atherogenic and neurodegenerative disorders. However, this process may become increasingly inefficient with aging, perhaps in part because of an insufficiency of adjuvant signals normally associated with infection that can program productive inflammatory states and properly orient the immune system toward regenerative healing. Here we propose conceptual foundations for exploring a small set of infection-associated molecules as potential immune adjuvants to reprogram non-productive inflammatory states in aging tissues, and to improve the clearance of cellular pathologies that engender age-associated disease. The proposed adjuvant classes include a subset of D-amino acids used by bacteria to disrupt biofilms; nucleoside derivatives of N6-methyladenine, which functions at the core of bacterial dam restriction systems; and derivatives of the galactosyl trisaccharide α-Gal, which invokes the hyperacute response in primates. These foreign amino acids, nucleosides and sugar molecules are generally rare or absent in humans, except in association with infections by bacteria, protists or nematodes. A rationale for exploration of these candidate adjuvant principles and their chemical derivatives is discussed in terms of their use in generalized strategies to improve the prevention or treatment of cancer and other age-associated diseases, as negative modifiers of aging.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Prendergast GC,Metz R

doi

10.4161/onci.21358

subject

Has Abstract

pub_date

2012-09-01 00:00:00

pages

924-929

issue

6

eissn

2162-4011

issn

2162-402X

pii

2012ONOIMM0227

journal_volume

1

pub_type

杂志文章
  • The Helicobacter pylori HopQ outermembrane protein inhibits immune cell activities.

    abstract::We previously showed that the colorectal cancer colonizing bacterium Fusobacterium nucleatum protects tumors from immune cell attack via binding of the fusbacterial Fap2 outer-membrane protein to TIGIT, a checkpoint inhibitory receptor expressed on T cells and NK cells. Helicobacter pylori, the causative agent for pep...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1553487

    authors: Gur C,Maalouf N,Gerhard M,Singer BB,Emgård J,Temper V,Neuman T,Mandelboim O,Bachrach G

    更新日期:2019-01-29 00:00:00

  • Immunoglobulin genes implicated in glioma risk.

    abstract::Both genetic and environmental factors are thought to be causal in gliomagenesis. Several genes have been implicated in glioma development, but the putative role of a major immunity-related gene complex member, immunoglobulin heavy chain γ (IGHG) has not been evaluated. Prior observations that IGHG-encoded γ marker (G...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.28609

    authors: Pandey JP,Kaur N,Costa S,Amorim J,Nabico R,Linhares P,Vaz R,Viana-Pereira M,Reis RM

    更新日期:2014-05-23 00:00:00

  • Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors.

    abstract::Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to pr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2015.1122158

    authors: Tsai AK,Davila E

    更新日期:2016-01-15 00:00:00

  • Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma.

    abstract::Efforts to reduce immunosuppression in the solid tumor microenvironment by blocking the recruitment or polarization of tumor associated macrophages (TAM), or myeloid derived suppressor cells (MDSCs), have gained momentum in recent years. Expanding our knowledge of the immune cell types, cytokines, or recruitment facto...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1507668

    authors: Moyes KW,Davis A,Hoglund V,Haberthur K,Lieberman NA,Kreuser SA,Deutsch GH,Franco S,Locke D,Carleton MO,Gilbertson DG,Simmons R,Winter C,Silber J,Gonzalez-Cuyar LF,Ellenbogen RG,Crane CA

    更新日期:2018-08-27 00:00:00

  • Th1 epitope selection for clinically effective cancer vaccines.

    abstract::New cancer immunotherapies mark progress in our understanding of tumor biology and harnessing the immune system's management of self. However, protein- and peptide-based vaccines are not yet consistently efficacious. Recent work uncovers principles governing the genesis of T helper type-restrictive immunity to self-an...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/21624011.2014.954971

    authors: Disis ML,Watt WC,Cecil DL

    更新日期:2014-12-13 00:00:00

  • In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer.

    abstract::Metastatic breast cancer remains an incurable disease. Most patients experience objective treatment responses associated with palliation of symptoms; however, progression inevitably occurs. Thus, there is an urgent need for innovative therapeutic strategies that may halt disease progression. Adoptive T-cell therapy is...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1055061

    authors: Thakur A,Lum LG

    更新日期:2015-07-15 00:00:00

  • LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.

    abstract::Immunotherapy with immune checkpoint molecule-specific monoclonal antibody have obtained encouraging results from preclinical studies and clinical trials, which promoted us to explore whether this kind of immunotherapy could be applicable to head and neck squamous cell carcinoma (HNSCC). Lymphocyte activation gene-3 (...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1239005

    authors: Deng WW,Mao L,Yu GT,Bu LL,Ma SR,Liu B,Gutkind JS,Kulkarni AB,Zhang WF,Sun ZJ

    更新日期:2016-10-07 00:00:00

  • PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance.

    abstract::The prognosis of high-risk neuroblastoma (NB) remains poor, although immunotherapies with anti-GD2 antibodies have been reported to provide some benefit. Immunotherapies can be associated with an IFNγ storm that induces in tumor cells the "adaptive immune resistance" characterized by the de-novo expression of Programm...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1064578

    authors: Dondero A,Pastorino F,Della Chiesa M,Corrias MV,Morandi F,Pistoia V,Olive D,Bellora F,Locatelli F,Castellano A,Moretta L,Moretta A,Bottino C,Castriconi R

    更新日期:2015-07-15 00:00:00

  • Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.

    abstract::Objective:Ovarian cancer (OC) is often diagnosed at an advanced stage with two thirds of patients experiencing recurrent disease with a poor prognosis. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has shown curative potential in malignant melanoma, but has only been investigated scarcely in ot...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1502905

    authors: Pedersen M,Westergaard MCW,Milne K,Nielsen M,Borch TH,Poulsen LG,Hendel HW,Kennedy M,Briggs G,Ledoux S,Nøttrup TJ,Andersen P,Hasselager T,Met Ö,Nelson BH,Donia M,Svane IM

    更新日期:2018-09-26 00:00:00

  • MDR1 in immunity: friend or foe?

    abstract::MDR1 is an ATP-dependent transmembrane transporter primarily studied for its role in the detoxification of tissues and for its implication in resistance of tumor cells to chemotherapy treatment. Several studies also report on its expression on immune cells where it plays a protective role from xenobiotics and toxins. ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2018.1499388

    authors: Bossennec M,Di Roio A,Caux C,Ménétrier-Caux C

    更新日期:2018-09-06 00:00:00

  • Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase.

    abstract::Tumor-associated macrophages play a central role in tumor progression and metastasis. Macrophages can also promote the resistance of malignant cells to chemotherapy by stimulating the upregulation of cytidine deaminase, an intracellular enzyme that catabolizes the active form of gemcitabine. Targeting macrophage-depen...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27231

    authors: Amit M,Gil Z

    更新日期:2013-12-01 00:00:00

  • Absence of myeloperoxidase and CD8 positive cells in colorectal cancer infiltrates identifies patients with severe prognosis.

    abstract::Colorectal cancer (CRC) infiltration by cells expressing myeloperoxidase (MPO) or CD8 positive T lymphocytes has been shown to be independently associated with favorable prognosis. We explored the relationship occurring between CD8+ and MPO+ cell CRC infiltration, its impact on clinical-pathological features and its p...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1050574

    authors: Däster S,Eppenberger-Castori S,Hirt C,Soysal SD,Delko T,Nebiker CA,Weixler B,Amicarella F,Iezzi G,Governa V,Padovan E,Mele V,Sconocchia G,Heberer M,Terracciano L,Kettelhack C,Oertli D,Spagnoli GC,von Holzen U,Tornil

    更新日期:2015-05-29 00:00:00

  • HDAC inhibitors and their potential applications to glioblastoma therapy.

    abstract::Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytot...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.25219

    authors: Adamopoulou E,Naumann U

    更新日期:2013-08-01 00:00:00

  • HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.

    abstract::The recent approval of clincially effective immune checkpoint inhibitors illustrates the potential of cancer immunotherapy. A challenging task remains the identification of specific targets guiding immunotherapy. Facilitated by technical advances, the direct identification of physiologically relevant targets is enable...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1065369

    authors: Peper JK,Bösmüller HC,Schuster H,Gückel B,Hörzer H,Roehle K,Schäfer R,Wagner P,Rammensee HG,Stevanović S,Fend F,Staebler A

    更新日期:2015-07-01 00:00:00

  • Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

    abstract::TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4-1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed, overexpression of A2...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1368605

    authors: Azpilikueta A,Bolaños E,Lang V,Labiano S,Aznar MA,Etxeberria I,Teijeira A,Rodriguez-Ruiz ME,Perez-Gracia JL,Jure-Kunkel M,Zapata JM,Rodriguez MS,Melero I

    更新日期:2017-09-21 00:00:00

  • A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells.

    abstract::Ibrutinib, a BTK inhibitor, is currently used to treat various hematological malignancies. We evaluated whether ibrutinib treatment during development of murine bone marrow-derived dendritic cells (DCs) modulates their maturation and activation. Ibrutinib treatment increased the proportion of CD11c(+) DCs, upregulated...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1151592

    authors: Natarajan G,Oghumu S,Terrazas C,Varikuti S,Byrd JC,Satoskar AR

    更新日期:2016-03-10 00:00:00

  • Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

    abstract::High-risk endometrial cancer (EC) is an aggressive disease for which new therapeutic options are needed. Aims of this study were to validate the enhanced immune response in highly mutated ECs and to explore immune profiles in other EC subgroups. We evaluated immune infiltration in 116 high-risk ECs from the TransPORTE...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1264565

    authors: Eggink FA,Van Gool IC,Leary A,Pollock PM,Crosbie EJ,Mileshkin L,Jordanova ES,Adam J,Freeman-Mills L,Church DN,Creutzberg CL,De Bruyn M,Nijman HW,Bosse T

    更新日期:2016-12-09 00:00:00

  • Tumor-infiltrating podoplanin+ cells in gastric cancer: clinical outcomes and association with immune contexture.

    abstract::Podoplanin (PDPN) has been proved to have significant immunoregulatory effects in several types of malignancies and is considered to be a novel immune checkpoint molecule. However, the clinical significance of PDPN and its potential influence on immune contexture in gastric cancer remain obscure. Here, we aimed to inv...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1845038

    authors: Liu X,Cao Y,Lv K,Gu Y,Jin K,He X,Fang H,Fei Y,Shi M,Lin C,Liu H,Li H,He H,Xu J,Li R,Zhang H

    更新日期:2020-11-13 00:00:00

  • Breaking the tolerance for tumor: Targeting negative regulators of TLR signaling.

    abstract::Tumors arise and progress in immunocompetent hosts presumably by activating tolerance mechanisms critical for normal homeostasis. Host immune cells can mount anti-tumor responses by activation of Toll-like receptors (TLRs). However, emerging data suggests that molecules that negatively regulate TLRs are exploited by t...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.18434

    authors: Standiford TJ,Keshamouni VG

    更新日期:2012-05-01 00:00:00

  • Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate.

    abstract::Somatic gain-of-function mutations in isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1) or isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2) are bona fide oncogenic drivers of acute myeloid leukemia and glioma because the neomorphic enzymes catalyze the synthesis of R-2-hydroxylutarate (R-2-HG), an oncom...

    journal_title:Oncoimmunology

    pub_type: 社论

    doi:10.1080/2162402X.2018.1528815

    authors: Galluzzi L,Kroemer G

    更新日期:2018-10-16 00:00:00

  • Trial watch: dietary interventions for cancer therapy.

    abstract::Dietary interventions have a profound impact on whole body metabolism, including oncometabolism (the metabolic features allowing cancer cells to proliferate) and immunometabolism (the catabolic and anabolic reactions that regulate immune responses). Recent preclinical studies demonstrated that multiple dietary changes...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2019.1591878

    authors: Lévesque S,Pol JG,Ferrere G,Galluzzi L,Zitvogel L,Kroemer G

    更新日期:2019-04-03 00:00:00

  • Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

    abstract::Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated through the IgG Fc receptor FcγRIIIa represents a major effector function of many therapeutic antibodies. In an attempt to further enhance natural killer (NK) cell-mediated ADCC, we combined therapeutic antibodies against CD20 and CD38 with recombinant immu...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1058459

    authors: Kellner C,Günther A,Humpe A,Repp R,Klausz K,Derer S,Valerius T,Ritgen M,Brüggemann M,van de Winkel JG,Parren PW,Kneba M,Gramatzki M,Peipp M

    更新日期:2015-06-05 00:00:00

  • Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset.

    abstract::Circulating fibrocytes were reported to represent a novel myeloid-derived suppressor cell (MDSC) subset and they were also proposed to be involved in the tumor immune escape. This novel fibrocyte subset had a surface phenotype resembling non-monocytic MDSCs (CD14-CD11chiCD123-) and exhibited immunomodulatory roles. Mo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1034918

    authors: Gunaydin G,Kesikli SA,Guc D

    更新日期:2015-05-27 00:00:00

  • Fbxw7 suppresses cancer metastasis by inhibiting niche formation.

    abstract::Fbxw7 has been identified as an oncosuppressor protein in many types of cancer. We have recently shown that loss of Fbxw7 in bone marrow-derived stromal cells (BMSCs) promotes cancer metastasis by increasing production of the chemokine CCL2, which attracts monocytic myeloid-derived suppressor cells (Mo-MDSCs) and macr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1022308

    authors: Yumimoto K,Nakayama KI

    更新日期:2015-06-03 00:00:00

  • Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer.

    abstract::The blockade of the PD-1 pathway can increase the production of interferon γ by tumor-specific T cells located within or in the proximity of the malignant lesion, thereby increasing the chemokine-dependent trafficking of immune effector cells. This can boost the efficacy of adoptive T-cell therapy to achieve superior ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.22691

    authors: Peng W,Lizée G,Hwu P

    更新日期:2013-02-01 00:00:00

  • A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway.

    abstract::A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.28440

    authors: Nagato T,Celis E

    更新日期:2014-05-15 00:00:00

  • Multiverse of immune microenvironment in metastatic colorectal cancer.

    abstract::The comprehensive analysis of patients with a complete resection of all metastases reveals the heterogeneity of the colorectal metastatic disease and its clinical impact. Complex tumor immune interrelations shape the metastatic landscape, not only in terms of number and size of lesions, or mutational pattern, but also...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1824316

    authors: Van den Eynde M,Mlecnik B,Bindea G,Galon J

    更新日期:2020-09-29 00:00:00

  • Fusions between dendritic cells and whole tumor cells as anticancer vaccines.

    abstract::Various strategies have been developed to deliver tumor-associated antigens (TAAs) to dendritic cells (DCs). Among these, the fusion of DCs and whole cancer cells can process a broad array of TAAs, including hitherto unidentified molecules, and present them in complex with MHC Class I and II molecules and in the conte...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.24437

    authors: Koido S,Homma S,Okamoto M,Namiki Y,Takakura K,Uchiyama K,Kajihara M,Arihiro S,Imazu H,Arakawa H,Kan S,Komita H,Ito M,Ohkusa T,Gong J,Tajiri H

    更新日期:2013-05-01 00:00:00

  • Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity.

    abstract::The inspection of the mechanisms through which autophagy modulates immunogenic cell death revealed that the autophagic response of cancer cells to reactive oxygen species-dependent endoplasmic reticulum stress suppresses the exposure of calreticulin on the cell surface, the phenotypic maturation of dendritic cells (DC...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26260

    authors: Garg AD,Dudek AM,Agostinis P

    更新日期:2013-10-01 00:00:00

  • Acute myeloid leukemia and NK cells: two warriors confront each other.

    abstract::Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerfu...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2018.1539617

    authors: Baragaño Raneros A,López-Larrea C,Suárez-Álvarez B

    更新日期:2018-10-31 00:00:00